Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
OBJECTIVE: In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies. STUDY DESIGN: Historical data on the HCV-infected populatio...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2015-11-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/2111 |
| _version_ | 1811194187140300800 |
|---|---|
| author | Philip Bruggmann Francesco Negro Florian Bihl Sarah Blach Daniel Lavanchy Beat Müllhaupt Homie Razavi David Semela |
| author_facet | Philip Bruggmann Francesco Negro Florian Bihl Sarah Blach Daniel Lavanchy Beat Müllhaupt Homie Razavi David Semela |
| author_sort | Philip Bruggmann |
| collection | DOAJ |
| description |
OBJECTIVE: In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies.
STUDY DESIGN: Historical data on the HCV-infected population in Switzerland were obtained from published literature, unpublished data and government reports. A disease progression model was used to age the infected population to 2015. The HCV distribution was then used to identify 5-year age cohorts with the highest HCV prevalence. The estimated number of cases needed to screen within an age cohort was calculated using the estimated viraemic prevalence, removing the percent previously diagnosed.
RESULTS: In 2015, the median age of the viraemic HCV infected population was 49 years, with 75% of the population born between 1951 and 1985. Random screening of the general population could identify one new viraemic HCV case per 159 persons screened, compared with targeted birth cohort screening, which could identify one new viraemic HCV case per 90–99 persons screened.
CONCLUSION: Considering only the direct cost of screening and treatment informing tests, targeted screening by birth cohort is more effective and cost effective than random screening in the general population.
|
| first_indexed | 2024-04-12T00:21:47Z |
| format | Article |
| id | doaj.art-e921cc11cb1a487ba52f77f95cca1dfb |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-12T00:21:47Z |
| publishDate | 2015-11-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-e921cc11cb1a487ba52f77f95cca1dfb2022-12-22T03:55:42ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972015-11-01145495010.4414/smw.2015.14221Birth cohort distribution and screening for viraemic hepatitis C virus infections in SwitzerlandPhilip BruggmannFrancesco NegroFlorian BihlSarah BlachDaniel LavanchyBeat MüllhauptHomie RazaviDavid Semela OBJECTIVE: In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies. STUDY DESIGN: Historical data on the HCV-infected population in Switzerland were obtained from published literature, unpublished data and government reports. A disease progression model was used to age the infected population to 2015. The HCV distribution was then used to identify 5-year age cohorts with the highest HCV prevalence. The estimated number of cases needed to screen within an age cohort was calculated using the estimated viraemic prevalence, removing the percent previously diagnosed. RESULTS: In 2015, the median age of the viraemic HCV infected population was 49 years, with 75% of the population born between 1951 and 1985. Random screening of the general population could identify one new viraemic HCV case per 159 persons screened, compared with targeted birth cohort screening, which could identify one new viraemic HCV case per 90–99 persons screened. CONCLUSION: Considering only the direct cost of screening and treatment informing tests, targeted screening by birth cohort is more effective and cost effective than random screening in the general population. https://www.smw.ch/index.php/smw/article/view/2111SwitzerlandscreeningdiagnosisHepatitis C virus (HCV)birth cohort |
| spellingShingle | Philip Bruggmann Francesco Negro Florian Bihl Sarah Blach Daniel Lavanchy Beat Müllhaupt Homie Razavi David Semela Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland Swiss Medical Weekly Switzerland screening diagnosis Hepatitis C virus (HCV) birth cohort |
| title | Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland |
| title_full | Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland |
| title_fullStr | Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland |
| title_full_unstemmed | Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland |
| title_short | Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland |
| title_sort | birth cohort distribution and screening for viraemic hepatitis c virus infections in switzerland |
| topic | Switzerland screening diagnosis Hepatitis C virus (HCV) birth cohort |
| url | https://www.smw.ch/index.php/smw/article/view/2111 |
| work_keys_str_mv | AT philipbruggmann birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland AT francesconegro birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland AT florianbihl birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland AT sarahblach birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland AT daniellavanchy birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland AT beatmullhaupt birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland AT homierazavi birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland AT davidsemela birthcohortdistributionandscreeningforviraemichepatitiscvirusinfectionsinswitzerland |